| |
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome overcome these challenges using AI cloud infrastructure and advanced machine learning tools. 
|
|
Today’s Big NewsFeb 7, 2025 |
|
Wednesday, February 26, 2025 | 11am ET / 8am PT Discover how the convergence of spatial biology, AI, and computational tools is transforming cancer research. This webinar explores high-multiplex spatial analysis, tumor heterogeneity, and advances in precision medicine, reshaping drug development. Register now to learn how these innovations are driving breakthroughs in oncology. 
|
|
| By Fraiser Kansteiner Bain Capital is laying out 510 billion Japanese yen ($3.3 billion) to acquire Mitsubishi Tanabe Pharma in a carve-out transaction from its parent Mitsubishi Chemical Group. The deal, which is expected to close in 2025’s third quarter, will set up Tanabe Pharma as an independent company, Bain said. |
|
|
|
By Nick Paul Taylor Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be Sotyktu successor. |
By Andrea Park Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for a corporate spot during the Super Bowl broadcast. Now, it seems to be becoming something of an annual tradition. |
By Angus Liu Johnson & Johnson's proposed $14.6 billion purchase of Intra-Cellular Therapies took just one month from the time the buyer revealed its intention to the signing of the deal. The process involved a key intervention from J&J’s CEO Joaquin Duato, a securities filing shows. |
|
Thursday, February 27, 2025 | 2pm ET / 11am PT The quest to discover biomarkers for therapeutic response through traditional genomic sequencing and other omic approaches has yet to deliver clinically actionable tools for most patients. Don’t miss this compelling discussion on how cutting-edge glycoproteomic technologies are unlocking new clinical insights. 
|
|
By Conor Hale The procedure was performed January 25 by surgeons at the Mass General Transplant Center in Boston, as part of the company’s clinical study in patients with end-stage renal disease and kidney failure. MGH previously completed the company’s first xenotransplant surgery, in March 2024. |
By Angus Liu Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward autoimmune diseases in 2024. Now, CEO Nadim Ahmed wants to reset expectations, hoping that speed and a “thriller or killer” approach will be his friends as the company navigates both competitive fields. |
By Conor Hale The DNA sequencing giant said it will continue to do business in China as long as it’s able—while also dealing with a decline in annual revenues. |
By Kevin Dunleavy Roche has detailed results of a phase 3 trial of its blood cancer drug Gazyva in lupus nephritis. The data set up the CD20 antibody for potential approval for what would be its most important indication. |
By Gabrielle Masson After sharing plans to shutter last summer, Asarina Pharma has managed to sell off its Tourette syndrome candidate to Relmada Therapeutics, another struggling biotech. |
By Andrea Park Since 1999, Feb. 7 has marked National Black HIV/AIDS Awareness Day, drawing attention to the disproportionate impact of HIV on Black communities. |
By Fraiser Kansteiner In a lawsuit that received little attention toward the end of last year, Regeneron has taken Sanofi to court over claims that its marketing and development partner violated the terms of a long-standing Dupixent collaboration. Regeneron disclosed the lawsuit in an annual filing this week. |
By Nick Paul Taylor Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to reductions in treated bleeds in children with the hereditary bleeding disorder. |
By Darren Incorvaia,Zoey Becker Veteran scientist Hideo Makimura, M.D., Ph.D., is going fully preclinical by joining gene therapy biotech Affinia Therapeutics as chief medical officer. Makimura most recently served in leadership roles at J&J. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we dig into the 10 biggest potential drug launches of 2025, predicted to rake in a combined $29 billion in annual sales by the end of the decade. |
|
|---|
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| Submissions Open Early August |
|
|
| |
|
